Nancy Lurker - Jan 3, 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jan 3, 2025
Transactions value $
$0
Form type
4
Date filed
1/7/2025, 04:04 PM
Previous filing
Aug 20, 2024
Next filing
Feb 5, 2025

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +40K $0.00 40K Jan 3, 2025 Common Stock 40K $8.26 Direct
transaction EYPT Restricted Stock Units Options Exercise $0 -12.7K -33.33% $0.00 25.3K Jan 5, 2025 Common Stock 12.7K $0.00 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -75.1K -50% $0.00 75.1K Jan 6, 2025 Common Stock 75.1K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The restricted stock units vests in three ratable annual installments beginning January 5, 2025.
F3 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.